Experience with gynestril in the treatment of patients with uterine myoma
- Autores: Levakov S.A.1, Kedrova A.G.1, Nechaeva O.E.1, Vanke N.S.1, Chelnokova N.N.2, Levakova S.E.3
-
Afiliações:
- Institute of Advanced Training, Federal Biomedical Agency of Russia
- Medical Sanitary Unit One Hundred Seventy, Federal Biomedical Agency of Russia
- Branch Two, City Polyclinic One Hundred Nine, Moscow Healthcare Department
- Edição: Nº 12 (2014)
- Páginas: 83-89
- Seção: Articles
- URL: https://journals.eco-vector.com/0300-9092/article/view/247318
- ID: 247318
Citar
Texto integral
Acesso está concedido
Acesso é pago ou somente para assinantes
Resumo
Palavras-chave
Texto integral
Sobre autores
Sergey Levakov
Institute of Advanced Training, Federal Biomedical Agency of Russia
Email: levakoff@yandex.ru
PhD, MD, Department of Obstetrics and Gynecology
Anna Kedrova
Institute of Advanced Training, Federal Biomedical Agency of Russia
Email: kedrova.anna@gmail.com
PhD, MD, Department of Obstetrics and Gynecology
Olga Nechaeva
Institute of Advanced Training, Federal Biomedical Agency of Russiadepartment of functional diagnostic and sonography
Nikita Vanke
Institute of Advanced Training, Federal Biomedical Agency of Russia
Email: wanke@rambler.ru
associate professor, Department of Obstetrics and Gynecology
Natalia Chelnokova
Medical Sanitary Unit One Hundred Seventy, Federal Biomedical Agency of Russia
Email: msdl70@extern.rsce.ru
Chief of the Gynecology department
Svetlana Levakova
Branch Two, City Polyclinic One Hundred Nine, Moscow Healthcare DepartmentDepartment of Obstetrics and Gynecology
Bibliografia
- Okolo S. Incidence, aetiology and epidemiology of uterine fibroids. Best Pract. Res. Clin. Obstet. Gynaecol. 2008; 22: 571-88.
- Леваков С.А., Кедрова А.Г., Ванке Н.С. Современный взгляд на комплексное лечение больных миомой матки. Клиническая практика. 2010; 3: 15-9. [Levakov S.A., Kedrova A.G., Vanke N.S. The modern view of the complex treatment of patients with uterine myoma. Klinicheskaya praktika. 2010; 3: 15-9. (In Russian)]
- Flynn M., Jamison M., Datta S., Myers E. Health care resource use for uterine fibroid tumors in the United States. Am. J. Obstet. Gynecol. 2006; 195 (4): 955-64.
- Zhang Q., Ubago J., Li L., Guo H., Liu Y., Qiang W. et al. Molecular analyses of 6 different types of uterine smooth muscle tumors: Emphasis in atypical leiomyoma. Cancer. 2014; 120 (20): 3165-77. doi: 10.1002/cncr.28900
- Ищенко А.И., Ботвин М.А., Ланчинский В.И. Миома матки. Этиология, патогенез, диагностика, лечение. М.: Видар-М; 2010: 32-4. [Ishchenko A.I., Botvin M.A., Lanchinskij V.I. Uterine fibroids. Etiology, pathogenesis, diagnosis, treatment. M.: Vidar-M; 2010: 32-4. (In Russian)]
- Radosa M.P., Owsianowski Z., Mothes A., Weisheit A., Vorwergk J., Asskaryar F.A. et al. Long-term risk of fibroid recurrence after laparoscopic myomectomy. Eur. J. Obstet. Gynecol. Reprod. Biol. 2014; 180: 35-9.
- Freed M.M., Spies J.B. Uterine artery embolization for fibroids: a review of current outcomes. Semin. Reprod. Med. 2010; 28: 235-41.
- Bifulco G., Miele C., Pellicano M., Trencia A., Ferraioli M., Paturzo F. et al. Molecular mechanisms involved in GnRH analogue-related apoptosis for uterine leiomyomas. Mol. Hum. Reprod. 2004; 10: 43-8.
- Ke L.Q., Yang K., Li J., Li C.M. Danazol for uterine fibroids. Cochrane Database Syst. Rev. 2009; (3): CD007692.
- Ying Z., Weiyuan Z. Dual actions of progesterone on uterine leiomyoma correlate with the ratio of progesterone receptor A:B. Gynecol. Endocrinol. 2009; 25 (8): 520-3.
- Ishikawa H., Kazutomo Ishi, Serna V.A. Progesterone is essential for maintenance and growth of uterine leiomyomas. Endocrinology. 2010; 151 (6): 2433-42
- Lamminen S., Rantala I., Helin H., Rorarius M., Tuimala R. Proliferative activity of human uterine leiomyoma cells as measured by automatic image analysis. Gynecol. Obstet. Invest. 1992; 34 (2): 111-4.
- Kawaguchi K., Fujii S., Konishi I., Nanbu Y., Nonogaki H., Mori T. Mitotic activity in uterine leiomyomas during the menstrual cycle. Am. J. Obstet. Gynecol. 1989; 160 (3): 637-41.
- Cutini P.H., Massheimer V.L. Role of progesterone on the regulation of vascular muscle cells proliferation, migration and apoptosis. Steroids. 2010; 75 (4-5): 355-61.
- Tiltman A.J. The effect of progestins on the mitotic activity of uterine fibromyomas. Int. J. Gynecol. Pathol. 1985; 4: 89-96.
- Engman M., Granberg S., Williams A.R., Meng C.X., Lalitkumar P.G., Gemzell-Danielsson K. Mifepristone for treatment of uterine leiomyoma. A prospective randomized placebo controlled trial. Hum. Reprod. 2009; 24 (8): 1870-9.
- Eisinger S.H., Bonfiglio T., Fiscella K., Meldrum S., Guzick D.S. Twelve month safety and efficacy of low-dose mifepristone for uterine myomas. J. Minim. Invasive Gynecol. 2005; 12 (3): 227-33.
- Fiscella K., Eisinger S.H., Meldrum S., Feng C., Fisher S.G., Guzick D.S. Effect of mifepristone for symptomatic leiomyomata on quality of life and uterine size: a randomized controlled trial. Obstet. Gynecol. 2006; 108 (6): 1381-7.
- Kim J.J., Sefton E.C. The role of progesterone signaling in the pathogenesis of uterine leiomyoma. Mol. Cell. Endocrinol. 2012; 358 (2): 223-31.
- Steinauer J., Pritts E. A., Jackson R., Jacoby A.F. Systematic review of mifepristone for the treatment of uterine leiomyomas. Obstet. Gynecol. 2004; 103 (6): 1331-6.
- Engman M., Skoog L., Söderqvist G., Gemzell-Danielsson K. The effect of mifepristone on breast cell proliferation in premenopausal women evaluated through fine needle aspiration cytology. Hum. Reprod. 2008; 23 (9): 2072-9.
- Baird D.T., Brown A., Critchley H.O., Williams A.R., Lin S., Cheng L. Effect of long-term treatment with low-dose mifepristone on the endometrium. Hum. Reprod. 2003; 18 (1): 6168-71.
- Lalitkumar P.G., Lalitkumar S., Meng C.X., Stavreus-Evers A., Hambiliki F., Bentin-Ley U., Gemzell-Danielsson K. Mifepristone, but not levonorgestrel, inhibits human blastocyst attachment to an in vitro endometrial threedimensional cell culture model. Hum. Reprod. 2007; 22 (11): 3031-7.
- Baird D.T., Brown A., Cheng L., Critchley H.O., Lin S., Narvekar N., Williams A.R. Mifepristone: a novel estrogen-free daily contraceptive pill. Steroids. 2003; 68 (10-13): 1099-105.
- Carboneil J.L., Acosta R., Pérez Y., Garcés R., Sánchez C., Tomasi G. Treatment of uterine myoma with 2.5 or 5 mg mifepristone daily during 3 months with 9 months posttreatment followup: randomized clinical trial. Obstet. Gynecol. 2013; 2013: 649030.
- Чекалова М.А., Кузнецов В.В., Захарова Т.И. Ультразвуковая диагностика лейомиом и сарком матки. Опухоли женской репродуктивной системы. 2008; 3: 62-6. [Chekalova M.A., Kuznecov V.V., Zaharova T.I. Ultrasound diagnosis of uterine leiomyomas and sarcomas. Opuholi zhenskoj reproduktivnoj sistemy. 2008; 3: 62-6. (In Russian)]
- Seth S., Goel N., Singh E., Mathur A.S., Gupta G. Effect of mifepristone 25mg in treatment of uterine myoma in perimenopausal woman. J. Midlife Health. 2013; 4 (1): 22-6.
- Стрижаков А.Н., Давыдов А.И., Пашков В.М., Лебедев В.А. Доброкачественные заболевания матки. М.: ГЭОТАР-Медиа; 2014. [Strizhakov A.N., Davydov A.I., Pashkov V.M., Lebedev V.A. Benign disease of the uterus. M.: GEHOTAR-Media; 2014. (In Russian)]
- Narvekar N., Cameron S., Critchley H.O., Lin S., Cheng L., Baird D.T. Low-dose mifepristone inhibits endometrial proliferation and upregulates androgen receptor. J. Clin. Endocrinol. Metab. 2004; 89 (5): 2491-7.